SS Innovations International (NASDAQ:SSII) Announces Quarterly Earnings Results

SS Innovations International (NASDAQ:SSII) posted its quarterly earnings data on Tuesday. The company reported ($0.01) earnings per share (EPS) for the quarter, Zacks reports. SS Innovations International had a negative net margin of 32.10% and a negative return on equity of 34.13%. The business had revenue of $14.53 million during the quarter.

SS Innovations International Stock Up 15.0%

Shares of NASDAQ:SSII traded up $0.67 during trading on Wednesday, reaching $5.09. 88,043 shares of the company traded hands, compared to its average volume of 99,467. The firm has a market capitalization of $988.32 million and a PE ratio of -101.70. SS Innovations International has a 52 week low of $3.02 and a 52 week high of $22.42. The company’s 50 day moving average is $4.82 and its two-hundred day moving average is $6.05.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of SS Innovations International in a report on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, SS Innovations International has a consensus rating of “Sell”.

Key Headlines Impacting SS Innovations International

Here are the key news stories impacting SS Innovations International this week:

• Positive Sentiment: CEO Srivastava purchased 498,753 shares (~$2.0M at ~$4.01), a meaningful insider buy that signals management confidence. SEC filing: Srivastava purchase
• Positive Sentiment: Director Timothy P. Adams bought 300,000 shares (~$1.2M at $3.99), increasing his stake — reinforces insider support. SEC filing: Adams purchase
• Positive Sentiment: Vice‑Chair Dr. Frederic H. Moll acquired 501,253 shares (~$2.0M at $3.99), adding to insider participation. SEC filing: Moll purchase
• Positive Sentiment: Company released Q4 and full‑year 2025 results showing strong growth in SSi Mantra installations, procedures and revenue — supports the growth narrative for device adoption. GlobeNewswire: Q4/FY2025 results
• Positive Sentiment: SS Innovations completed an $18.6M private placement to fund U.S./EU expansion and working capital — provides near‑term cash to support commercialization efforts. GlobeNewswire: Private placement
• Neutral Sentiment: Some institutional investors have added positions recently, which could support liquidity and longer‑term demand but may not alter near‑term volatility. QuiverQuant: ownership/placement summary
• Negative Sentiment: Company reported a small quarterly loss (EPS $(0.01)) with a negative net margin (~‑32.1%) and negative ROE (~‑34.1%), underscoring that profitability is still distant. MarketBeat: earnings summary
• Negative Sentiment: The private placement issued ~5.77M new shares and included unregistered securities/warrants to a FINRA firm — this raises dilution and registration/liquidity concerns. GlobeNewswire: private placement terms
• Negative Sentiment: Regulatory timing (FDA 510(k) review expected mid‑2026 and CE efforts) creates execution risk; outcomes and timing will strongly affect the share path. GlobeNewswire: regulatory timeline
• Negative Sentiment: Analyst coverage is limited and includes a recent Sell (Weiss Ratings) — a reminder of continued skepticism among some research shops. Weiss Ratings: research note

Insider Buying and Selling

In other news, Director Frederic H. Moll acquired 501,253 shares of the business’s stock in a transaction that occurred on Friday, March 6th. The stock was acquired at an average price of $3.99 per share, with a total value of $1,999,999.47. Following the completion of the transaction, the director directly owned 10,775,485 shares of the company’s stock, valued at $42,994,185.15. This trade represents a 4.88% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Srivastava Sudhir acquired 498,753 shares of SS Innovations International stock in a transaction on Friday, March 6th. The shares were purchased at an average price of $4.01 per share, for a total transaction of $1,999,999.53. Following the completion of the purchase, the chief executive officer directly owned 109,851,767 shares of the company’s stock, valued at approximately $440,505,585.67. This represents a 0.46% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have purchased 1,300,006 shares of company stock worth $5,196,999.

Hedge Funds Weigh In On SS Innovations International

Several hedge funds and other institutional investors have recently made changes to their positions in the company. PNC Financial Services Group Inc. bought a new stake in shares of SS Innovations International during the 3rd quarter worth approximately $56,000. Jane Street Group LLC bought a new position in SS Innovations International in the fourth quarter valued at approximately $63,000. IFC & Insurance Marketing Inc. acquired a new position in SS Innovations International during the fourth quarter valued at approximately $64,000. Goldman Sachs Group Inc. acquired a new position in SS Innovations International during the fourth quarter valued at approximately $68,000. Finally, Envestnet Asset Management Inc. bought a new stake in SS Innovations International during the third quarter worth $71,000.

About SS Innovations International

AVRA Medical Robotics, Inc develops and manufactures medical surgical devices. The company has a research agreement with the University of Central Florida to develop navigation and control technologies with applications in medical robotics. The company was formerly known as AVRA Surgical Microsystems, Inc and changed its name to AVRA Medical Robotics, Inc in November 2015. AVRA Medical Robotics, Inc was founded in 2015 and is based in Orlando, Florida.